Abstract
BackgroundThe phase 2/3 RELATIVITY-047 clinical trial (NCT03470922) in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of improved progression-free survival with a combination of nivolumab plus...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have